Cooper Kept the Unit and Lost the Premium in One Session
Cooper Companies just killed the deal dream and the stock paid cash for it.
Shares of Cooper Companies (COO) got crushed after the contact-lens and women's-health company posted mixed fiscal third-quarter results, cut the near-term outlook, and told investors it will keep CooperSurgical after a full strategic review. The stock slid roughly 15% on the session and paced the S&P 500's worst names.
Adjusted earnings came in at about $1.15 a share, a slight beat. Revenue near $1.07 billion missed the Street. The real punch was fiscal fourth-quarter guidance: adjusted EPS of $1.05 to $1.09 on revenue of about $1.06 to $1.08 billion, well under consensus near $1.19 and $1.11 billion.
The sale that never came
For months, a chunk of the bull case was simple. Someone might buy CooperSurgical. The board finished the review and said no. Keep the unit. Focus on profitable growth, cash flow, and capital returns. The buyback authorization jumped to $3 billion from $2 billion. That is real money. It is not the takeover story the tape had been pricing.
CooperVision is still cleaning out U.S. channel inventory. Management said that drag keeps hurting the vision side into the fourth quarter. Analysts cut targets in a hurry. Baird moved to Neutral. Needham, JPMorgan, UBS, and BofA all pulled numbers lower even where ratings stayed put.
What the tape is saying
I do not need a soap opera about missed synergy theater. This is a medical-device name that beat on adjusted earnings and still got hammered because the growth path got smaller and the deal catalyst walked off stage at the same time. Share buybacks help patient holders through a rough quarter, but they do not fix distributor destocking overnight or restore a multiple that was partly built on sale speculation.
As for me, I care whether CooperVision can finish the inventory clean and show organic growth that does not need a sale rumor to hold the multiple through the next couple of reports. Until that durability shows up in the numbers, this looks like a story about patience and execution rather than celebration.
Bottom line: Cooper kept CooperSurgical, cut the guide, and the market took the deal premium out of the stock in one session.
Money Morning is not a registered investment advisor. This article is for informational purposes only and should not be construed as investment advice. Past performance is not indicative of future results. We may receive compensation for promoting third-party products and services. Always do your own due diligence before investing.